AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9554662 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect technique (spitting action)
Number of subjects: 20
Study 9554662 — intervention group
Group type: COMPARATOR
Intervention: Correct technique
Number of subjects: 20
Study 8092508 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanolone 0.6 mg/kg
Number of subjects: 8
Study 8092508 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 8
Study 3046851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime (CDZ) - 2 g daily dose i.v. for 6 days to patients and for 4 days to healthy subjects.
Number of subjects: 24
Study 3046851 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects receiving CDZ at 0800 or 1800.
Number of subjects: 24
Study 30304237 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (50 mg/kg daily)
Number of subjects: 0
Study 30304237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28734717 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice a day for 7 days)
Number of subjects: 74
Study 28734717 — intervention group
Group type: COMPARATOR
Intervention: No drug (standard of care)
Number of subjects: 74
Study 26651470 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive
Number of subjects: 492
Study 26651470 — intervention group
Group type: EXPERIMENTAL
Intervention: Both (passive + active)
Number of subjects: 492
Study 23703407 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline combined with triamcinolone
Number of subjects: 68
Study 23703407 — intervention group
Group type: COMPARATOR
Intervention: Normal saline combined with triamcinolone
Number of subjects: 68
Study 21990307 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g/d ginger
Number of subjects: 30
Study 21990307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18433023 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 173
Study 18433023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 16497273 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 90
Study 16497273 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 90
Study 16497273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 12956319 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (0.4 g x d(‐1))
Number of subjects: 12
Study 12956319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12956319 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 12
Study 11831450 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol, twice daily for 4 weeks
Number of subjects: 19
Study 11831450 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 4 weeks
Number of subjects: 19
Study 11831450 — intervention group
Group type: COMPARATOR
Intervention: Formoterol vs. Placebo
Number of subjects: 19
Study 9605722 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoseizures
Number of subjects: 68
Study 9605722 — intervention group
Group type: COMPARATOR
Intervention: Complex partial seizures
Number of subjects: 68
Study 9605722 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life in Epilepsy Inventory‐89
Number of subjects: 68
Study 7847595 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg daily)
Number of subjects: 30
Study 7847595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3293733 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol
Number of subjects: 15
Study 31467052 — intervention group
Group type: EXPERIMENTAL
Intervention: New service delivery model including case management, counselling, AAC training, and AAC therapy.
Number of subjects: 0
Study 31467052 — intervention group
Group type: COMPARATOR
Intervention: Standard care provided to AAC users.
Number of subjects: 0
Study 28335810 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless Learning (EL)
Number of subjects: 161
Study 28335810 — intervention group
Group type: COMPARATOR
Intervention: Trial and Error Learning (TEL)
Number of subjects: 161
Study 26032132 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 69
Study 23650701 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery plus small windows through canine fossa surgery
Number of subjects: 50
Study 23650701 — intervention group
Group type: COMPARATOR
Intervention: Simple endoscopic surgery
Number of subjects: 50
Study 21636796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 278
Study 21636796 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 278
Study 19567526 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5-h bedtime
Number of subjects: 11
Study 19567526 — intervention group
Group type: COMPARATOR
Intervention: 8.5-h bedtime
Number of subjects: 11
Study 16735016 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype mask (from Carburos Metálicos)
Number of subjects: 35
Study 16735016 — intervention group
Group type: COMPARATOR
Intervention: Profile Lite nasal mask (Respironics)
Number of subjects: 35
Study 16735016 — intervention group
Group type: COMPARATOR
Intervention: ComfortClassic nasal mask (Respironics)
Number of subjects: 35
Study 16279281 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 0
Study 16279281 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 11309556 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily for 7 days
Number of subjects: 16
Study 11309556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9295896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparine 3075 IU AXa (fixed dosage)
Number of subjects: 150
Study 9295896 — intervention group
Group type: COMPARATOR
Intervention: Fraxiparine 4100 or 6150 IU AXa (dosage adjusted for body weight)
Number of subjects: 150
Study 8314476 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b, 3 million units subcutaneously, thrice weekly for 12 months
Number of subjects: 18
Study 8314476 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b, 3 million units subcutaneously, for 6 months (after initial control period)
Number of subjects: 18
Study 8314476 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 18
Study 8314476 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (12 months treatment)
Number of subjects: 18
Study 8314476 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18
Study 31722130 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS4BG text-message diabetes self-management support programme for 9 months
Number of subjects: 366
Study 31722130 — intervention group
Group type: COMPARATOR
Intervention: Usual care for 9 months
Number of subjects: 366
Study 31722130 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intervention vs control
Number of subjects: 366
Study 31477677 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy®
Number of subjects: 150
Study 31477677 — intervention group
Group type: EXPERIMENTAL
Intervention: ShotBlocker®
Number of subjects: 150
Study 31477677 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 28636674 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Behavior Change Communication (BCC) intervention
Number of subjects: 900
Study 25925674 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (standard daily dose)
Number of subjects: 120
Study 25925674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 22946864 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-professional educational programme
Number of subjects: 128
Study 22946864 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study 22179917 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg Misoprostol sublingually, 2 hours before diagnostic hysteroscopy
Number of subjects: 108
Study 22179917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prior preparation)
Number of subjects: 108
Study 22179917 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg Misoprostol sublingually, 2 hours before diagnostic hysteroscopy (in postmenopausal women)
Number of subjects: 108
Study 22179917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prior preparation, in postmenopausal women)
Number of subjects: 108
Study 22179917 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg Misoprostol sublingually, 2 hours before diagnostic hysteroscopy (in patients with a history of vaginal delivery)
Number of subjects: 108
Study 22179917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prior preparation, in patients with a history of vaginal delivery)
Number of subjects: 108
Study 18640769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightly vardenafil
Number of subjects: 628
Study 18640769 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand vardenafil
Number of subjects: 628
Study 18640769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study 16646125 — intervention group
Group type: EXPERIMENTAL
Intervention: MTBI patients with PCS
Number of subjects: 26
Study 16646125 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic MTBI participants
Number of subjects: 26
Study 16646125 — intervention group
Group type: COMPARATOR
Intervention: Matched normal control (NC) subjects
Number of subjects: 26
Study 12514660 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 312
Study 12858920 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal dihydroartemisinin (DATM)
Number of subjects: 67
Study 12858920 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 67
Study 8807058 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) plus didanosine (group 1)
Number of subjects: 85
Study 8807058 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV plus didanosine plus escalating doses (400 to 1,200 mg/day) of delavirdine (DLV) (group 2)
Number of subjects: 85
Study 8807058 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg of DLV alone per day (group 3)
Number of subjects: 85
Study 8807058 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV plus 1,200 mg of DLV per day (group 4)
Number of subjects: 85
Study 1737588 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients from the EORTC trial 10801, which addresses breast conserving procedures.
Number of subjects: 0
Study 1737588 — intervention group
Group type: COMPARATOR
Intervention: Matched controls from the historical group (1960-1974).
Number of subjects: 0
Study 6393814 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine and antacids
Number of subjects: 66
Study 6393814 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 66
Study 6393814 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 66
Study 30784637 — intervention group
Group type: EXPERIMENTAL
Intervention: Child development programme sessions (25 sessions)
Number of subjects: 1737
Study 30784637 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1737
Study 30384629 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap-junction coupled neurons with increasing coupling strength
Number of subjects: 0
Study 30384629 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurons with limited diversity (specific patterns removed)
Number of subjects: 0
Study 27097646 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance-based after-school intervention
Number of subjects: 31
Study 25210016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab retreatment at 10 mg/kg
Number of subjects: 0
Study 25210016 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab induction at 0.3 mg/kg
Number of subjects: 0
Study 25210016 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab induction at 3 mg/kg
Number of subjects: 0
Study 25210016 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab induction at 10 mg/kg
Number of subjects: 0
Study 25210016 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab induction at 3 mg/kg (treatment-naive)
Number of subjects: 0
Study 25210016 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab induction at 10 mg/kg (treatment-naive)
Number of subjects: 0
Study 25210016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab retreatment (0.3 mg/kg)
Number of subjects: 0
Study 25210016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab retreatment (3 mg/kg)
Number of subjects: 0
Study 25210016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab retreatment (10 mg/kg)
Number of subjects: 0
Study 21544639 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR)
Number of subjects: 38
Study 21544639 — intervention group
Group type: COMPARATOR
Intervention: Conventional segmental self‐stretching and breathing exercises (Control)
Number of subjects: 38
Study 20854678 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment of HV using the Manchester scale
Number of subjects: 138
Study 20854678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomised Manchester scale scores
Number of subjects: 138
Study 17229252 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide
Number of subjects: 32
Study 17229252 — intervention group
Group type: COMPARATOR
Intervention: Control group (other disease-modifying anti-rheumatic drug therapies)
Number of subjects: 32
Study 15150139 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated cartoons
Number of subjects: 0
Study 15150139 — intervention group
Group type: COMPARATOR
Intervention: Printed message about polio vaccinations
Number of subjects: 0
Study 12237643 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 24
Study 12237643 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 24
Study 9850907 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-piece PMMA IOL
Number of subjects: 70
Study 9850907 — intervention group
Group type: COMPARATOR
Intervention: 3-piece silicone IOL
Number of subjects: 70
Study 7989477 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 85
Study 7989477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 2682980 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-8980
Number of subjects: 95
Study 2682980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 30188382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan enhancement
Number of subjects: 164
Study 30188382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 164
Study 30188382 — intervention group
Group type: COMPARATOR
Intervention: Sham day
Number of subjects: 164
Study 27889574 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Oral Suspension (BOS) 2 mg twice daily for 12 weeks
Number of subjects: 93
Study 27889574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 25925220 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline echocardiographic measures (LVEDV, LVEF, GLS) in patients treated with anthracyclines
Number of subjects: 158
Study 25925220 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline echocardiographic measures (GLS) in patients treated with anthracyclines
Number of subjects: 158
Study 23909040 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaxol
Number of subjects: 100
Study 23909040 — intervention group
Group type: COMPARATOR
Intervention: Essentale
Number of subjects: 100
Study 20649445 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualization of group members in a homogeneous way
Number of subjects: 0
Study 20649445 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visualization)
Number of subjects: 0
Study 19306961 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNF-R2 levels at enrollment (24-28 weeks gestation)
Number of subjects: 986
Study 19306961 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNF-R2 levels at weeks 24-28
Number of subjects: 986
Study 19306961 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNF-R2 levels in the highest quartile at week 24-28
Number of subjects: 986
Study 19306961 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 986
Study 19306961 — intervention group
Group type: COMPARATOR
Intervention: Aspirin group
Number of subjects: 986
Study 16425094 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated skin screening clinics (Group B)
Number of subjects: 3110
Study 16425094 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrally organised skin screening clinics (Group C)
Number of subjects: 3110
Study 16425094 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin screening within day‐to‐day primary care (Group A)
Number of subjects: 3110
Study 16425094 — intervention group
Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 3110
Study 14641357 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild soaps (8 different products)
Number of subjects: 0
Study 10764435 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC (cisplatin 50 mg/m², vincristine 1 mg/m² for 1 day, bleomycin 25 mg/m² for 3 days for three cycles followed by radical hysterectomy
Number of subjects: 124
Study 10764435 — intervention group
Group type: COMPARATOR
Intervention: R/T (primary pelvic radiotherapy only)
Number of subjects: 124
Study 8820790 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologists' agreement with index diagnosis (excluding minor discrepancies)
Number of subjects: 16
Study 8820790 — intervention group
Group type: EXPERIMENTAL
Intervention: Major discrepancies in diagnoses
Number of subjects: 16
Study 8820790 — intervention group
Group type: EXPERIMENTAL
Intervention: Misdiagnosis of biopsy findings
Number of subjects: 16
Study 8820790 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement
Number of subjects: 16
Study 1444609 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (40 mg weekly for 8 weeks, with two additional instillations every 15 days in 50 ml saline)
Number of subjects: 57
Study 1444609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (20 mg weekly for 8 weeks, with two additional instillations every 15 days in 50 ml saline)
Number of subjects: 57
Study 1444609 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 57
Study 1444609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 57
Study 2932307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleocin T Topical 1 percent Solution
Number of subjects: 0
Study 2932307 — intervention group
Group type: COMPARATOR
Intervention: Cleocin T Topical 1 percent Lotion
Number of subjects: 0
Study 31089709 — intervention group
Group type: EXPERIMENTAL
Intervention: High circulating microseminoprotein-beta (MSP) concentrations
Number of subjects: 1871
Study 31089709 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR) analysis
Number of subjects: 1871
Study 31089709 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational analysis from EPIC
Number of subjects: 1871
Study 28663395 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block with 75 mg of 0.25% levobupivacaine hydrochloride
Number of subjects: 264
Study 28663395 — intervention group
Group type: COMPARATOR
Intervention: Periarticular infiltration with 150 mg of 0.25% levobupivacaine hydrochloride, 10 mg morphine sulphate, 30 mg ketorolac trometamol, 0.25 mg of adrenaline diluted with 0.9% saline to 150 ml
Number of subjects: 264
Study 26330144 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain-enriched diet (WGDG)
Number of subjects: 27
Study 26330144 — intervention group
Group type: COMPARATOR
Intervention: Refined grain diet (RDG)
Number of subjects: 27
Study 23474642 — intervention group
Group type: EXPERIMENTAL
Intervention: tele‐SEGT (supportive‐expressive group therapy)
Number of subjects: 361
Study 23474642 — intervention group
Group type: EXPERIMENTAL
Intervention: tele‐CET (coping effectiveness training)
Number of subjects: 361
Study 23474642 — intervention group
Group type: COMPARATOR
Intervention: SOC (standard of care)
Number of subjects: 361
Study 21208082 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 15
Study 21208082 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 15
Study 19725253 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium (150 mg per day)
Number of subjects: 10
Study 19725253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17964975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (7 mg/kg every 8 h)
Number of subjects: 50
Study 17964975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15094573 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine 1 mg/kg
Number of subjects: 126
Study 15094573 — intervention group
Group type: EXPERIMENTAL
Intervention: IV midazolam 0.15 mg/kg
Number of subjects: 126
Study 15094573 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine 1 mg/kg plus IV midazolam 0.1 mg/kg
Number of subjects: 126
Study 15094573 — intervention group
Group type: EXPERIMENTAL
Intervention: IV midazolam 0.1 mg/kg plus IV fentanyl 2 microg/kg
Number of subjects: 126
Study 15094573 — intervention group
Group type: EXPERIMENTAL
Intervention: IV propofol 2 mg/kg
Number of subjects: 126
Study 11820726 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of bovine pancreatic chymotrypsin
Number of subjects: 0
Study 11820726 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of papain
Number of subjects: 0
Study 11820726 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of bacterial protease from Bacillus licheniformis
Number of subjects: 0
Study 11820726 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Alcalase
Number of subjects: 0
Study 11820726 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Optimase
Number of subjects: 0